KR102442369B1 - Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법 - Google Patents

Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법 Download PDF

Info

Publication number
KR102442369B1
KR102442369B1 KR1020207015467A KR20207015467A KR102442369B1 KR 102442369 B1 KR102442369 B1 KR 102442369B1 KR 1020207015467 A KR1020207015467 A KR 1020207015467A KR 20207015467 A KR20207015467 A KR 20207015467A KR 102442369 B1 KR102442369 B1 KR 102442369B1
Authority
KR
South Korea
Prior art keywords
crystalline form
compound
formula
ray powder
powder diffraction
Prior art date
Application number
KR1020207015467A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078607A (ko
Inventor
차오펑 롱
양 장
정시아 천
시아오신 천
주오웨이 류
메이비 다이
지치앙 류
슈후이 천
Original Assignee
광동 쫑성 파마세티컬 컴패니, 리미티드
광동 시안치앙 파마슈티칼 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광동 쫑성 파마세티컬 컴패니, 리미티드, 광동 시안치앙 파마슈티칼 컴퍼니 리미티드 filed Critical 광동 쫑성 파마세티컬 컴패니, 리미티드
Publication of KR20200078607A publication Critical patent/KR20200078607A/ko
Application granted granted Critical
Publication of KR102442369B1 publication Critical patent/KR102442369B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207015467A 2017-11-01 2018-10-30 Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법 KR102442369B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711059786.4 2017-11-01
CN201711059786 2017-11-01
PCT/CN2018/112659 WO2019085893A1 (zh) 2017-11-01 2018-10-30 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法

Publications (2)

Publication Number Publication Date
KR20200078607A KR20200078607A (ko) 2020-07-01
KR102442369B1 true KR102442369B1 (ko) 2022-09-08

Family

ID=66332833

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015467A KR102442369B1 (ko) 2017-11-01 2018-10-30 Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법

Country Status (10)

Country Link
US (1) US11440903B2 (zh)
EP (1) EP3712146A4 (zh)
JP (1) JP7076565B2 (zh)
KR (1) KR102442369B1 (zh)
CN (1) CN111315741B (zh)
AU (1) AU2018361264B2 (zh)
CA (1) CA3080827A1 (zh)
IL (1) IL274274B2 (zh)
TW (1) TWI793207B (zh)
WO (1) WO2019085893A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754218A (en) * 2016-11-17 2021-07-30 Guangdong Zhongsheng Pharmaceutical Co Ltd Fgfr4 inhibitor and preparation method and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
JP6458023B2 (ja) * 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
NZ754218A (en) 2016-11-17 2021-07-30 Guangdong Zhongsheng Pharmaceutical Co Ltd Fgfr4 inhibitor and preparation method and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Also Published As

Publication number Publication date
TWI793207B (zh) 2023-02-21
CN111315741B (zh) 2023-01-24
US11440903B2 (en) 2022-09-13
AU2018361264A1 (en) 2020-06-04
IL274274B2 (en) 2023-11-01
KR20200078607A (ko) 2020-07-01
TW201922733A (zh) 2019-06-16
JP7076565B2 (ja) 2022-05-27
CN111315741A (zh) 2020-06-19
JP2021501212A (ja) 2021-01-14
WO2019085893A1 (zh) 2019-05-09
US20210087181A1 (en) 2021-03-25
IL274274A (en) 2020-06-30
CA3080827A1 (en) 2019-05-09
IL274274B1 (en) 2023-07-01
EP3712146A4 (en) 2021-05-05
AU2018361264B2 (en) 2021-04-01
EP3712146A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
ES2960702T3 (es) Formas cristalinas C y E del compuesto de pirazin-2(1H)-ona y método de preparación de las mismas
US10766862B2 (en) Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
KR102442369B1 (ko) Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
CN114174270B (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
JP6974618B2 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤としての化合物の塩形態、結晶形およびその製造方法
Guo et al. Spin‐labeled derivatives of cardiotonic steroids as tools for characterization of the extracellular entrance to the binding site on Na+, K+‐ATP ase
AU2020287139A1 (en) Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
WO2019114741A1 (zh) 作为Akt抑制剂的盐型及其晶型
CN109563097A (zh) 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
BR112021014327A2 (pt) Forma cristalina de derivado de 1,2,3-triazolo[1,5-a]pirazinas, método de preparação da referida forma cristalina, composições farmacêuticas compreendendo a mesma e seu uso
CN104870437A (zh) 三嗪化合物、其药用盐、异构体或水合物及其药物组合物
WO2019057121A1 (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
RU2818103C2 (ru) Соль ингибитора syk и ее кристаллическая форма
Tian et al. Design, synthesis, antitumor evaluation, 3D-QSAR and molecular docking studies of novel 4-aminoacridone compounds
Bhakta et al. Design, synthesis, molecular docking and anti-proliferative activity of novel phenothiazine containing imidazo [1, 2-a] pyridine derivatives against MARK4 protein
CN117946168A (zh) 含磷吡啶并[2,3-d]嘧啶-7-酮的甲磺酸盐的新晶型、药物组合物和应用
CN116836149A (zh) 吡嗪硫联苯基类化合物的晶型及其应用

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant